Tandem transplantation in lymphoma.
The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.
Papadopoulos
K P
KP
Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Noguera-Irizarry
W
W
Hesdorffer
C S
CS
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D016879:Salvage Therapy / Q000379:methods*; D014182:Transplantation, Autologous